Abstract:Parasites of the genus Leishmania pose a global health threat with limited treatment options. New drugs are urgently needed, and genomic screens have the potential to accelerate target discovery, mode of action, and resistance mechanisms against these new drugs. We describe here our effort in developing a genome-wide CRISPR-Cas9 screen in Leishmania, an organism lacking a functional nonhomologous end joining system that must rely on microhomology-mediated end joining, single-strand annealing, or homologous recombination for repairing Cas9-induced double-stranded DNA breaks. A new vector for cloning and expressing single guide RNAs (sgRNAs) was designed and proven to be effective in a small pilot project while enriching specific sgRNAs during drug selection. We then developed a whole-genome library of 49,754 sgRNAs, targeting all the genes of Leishmania infantum. This library was transfected in L. infantum expressing Cas9, and these cells were selected for resistance to two antileishmanials, miltefosine and amphotericin B. The sgRNAs the most enriched in the miltefosine screen targeted the miltefosine transporter gene, but sgRNAs targeting genes coding for a RING-variant protein and a transmembrane protein were also enriched. The sgRNAs the most enriched by amphotericin B targeted the sterol 24 C methyltransferase genes and a hypothetical gene. Through gene disruption experiments, we proved that loss of function of these genes was associated with resistance. This study describes the feasibility of carrying out whole-genome CRISPR-Cas9 screens in Leishmania provided that a strong selective pressure is applied. Such a screen can be used for accelerating the development of urgently needed antileishmanial drugs.IMPORTANCELeishmaniasis, a global health threat, lacks adequate treatment options and drug resistance exacerbates the challenge. This study introduces a CRISPR-Cas9 screening approach in Leishmania infantum, unraveling mechanisms of drug resistance at a genome-wide scale. Our screen was applied against two main antileishmanial drugs, and guides were enriched upon drug selection. These guides targeted known and new targets, hence validating the use of this screen against Leishmania. This strategy provides a powerful tool to expedite drug discovery as well as potential therapeutic targets against this neglected tropical disease.

CRISPR/Cas9 and genetic screens in malaria parasites: small genomes, big impact

A scalable CRISPR-Cas9 gene editing system facilitates CRISPR screens in the malaria parasite

Cutting back malaria: CRISPR/Cas9 genome editing of Plasmodium

A CRISPR homing screen finds a chloroquine resistance transporter-like protein of the Plasmodium oocyst essential for mosquito transmission of malaria

The dCas9-based genome editing in Plasmodium yoelii

CRISPR-Cas13 in malaria parasite: Diagnosis and prospective gene function identification

Whole‐genome CRISPR screens to understand Apicomplexan–host interactions

Constitutive expression of Cas9 and rapamycin-inducible Cre recombinase facilitates conditional genome editing in Plasmodium berghei

New and emerging uses of CRISPR/Cas9 to genetically manipulate apicomplexan parasites

CRISPR-mediated genome editing of Plasmodium falciparum malaria parasites

A genome-wide CRISPR screen in Anopheles mosquito cells identifies essential genes and required components of clodronate liposome function

Optimization of CRISPR/Cas System for Improving Genome Editing Efficiency in Plasmodium falciparum

Highly Efficient Site-Specific Mutagenesis in Malaria Mosquitoes Using CRISPR

CRISPR/Cas9 gene editing: Applications in Parasitology

Genome Editing by CRISPR/Cas9: A Game Change in the Genetic Manipulation of Protists

Host cell CRISPR genomics and modelling reveal shared metabolic vulnerabilities in the intracellular development of Plasmodium falciparum and related hemoparasites

Breaking Boundaries in Malaria Research: Design of a Genetic Tool for High-Throughput Gametocidal Drug Screening

CRISPR-Cas9 high-throughput screening to study drug resistance in Leishmania infantum

A novel chemogenomic screening platform for scalable antimalarial drug target identification

Highly efficient Cas9-mediated gene drive for population modification of the malaria vector mosquito Anopheles stephensi

Advances in the application of genetic manipulation methods to apicomplexan parasites